streptozocin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2483 18883-66-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • streptozocin
  • estreptozocin
  • streptozoticin
  • streptozotocin
  • zanosar
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
  • Molecular weight: 265.22
  • Formula: C8H15N3O7
  • CLOGP: -1.42
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 5
  • TPSA: 151.92
  • ALOGS: -0.90
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 407.20 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 21 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 7, 1982 FDA TEVA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephropathy toxic 95.03 58.69 17 139 8012 50596956
Chronic kidney disease 62.90 58.69 16 140 39755 50565213

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephropathy toxic 71.20 49.50 17 343 17497 64480875
Left ventricular dysfunction 51.32 49.50 13 347 16941 64481431
Chronic kidney disease 51.08 49.50 17 343 57902 64440470

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AD04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Nitrosoureas
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:59517 DNA synthesis inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pancreatic Neuroendocrine Tumor indication 717919005
Carcinoid syndrome off-label use 35868009
Mycosis contraindication 3218000 DOID:1564
Viral disease contraindication 34014006 DOID:934
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Leukopenia contraindication 84828003 DOID:615
Bacterial infectious disease contraindication 87628006
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Protozoal Infection contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.1 acidic
pKa2 12.56 acidic
pKa3 13.33 acidic
pKa4 13.57 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018094 VUID
N0000146432 NUI
D05932 KEGG_DRUG
4018094 VANDF
C0038432 UMLSCUI
CHEBI:9288 CHEBI
STZ PDB_CHEM_ID
CHEMBL1651906 ChEMBL_ID
DB00428 DRUGBANK_ID
D013311 MESH_DESCRIPTOR_UI
29327 PUBCHEM_CID
3824 INN_ID
5W494URQ81 UNII
10114 RXNORM
1423 MMSL
5515 MMSL
d00375 MMSL
002663 NDDF
16915004 SNOMEDCT_US
404876000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zanosar HUMAN PRESCRIPTION DRUG LABEL 1 0703-4636 POWDER, FOR SOLUTION 100 mg INTRAVENOUS NDA 18 sections